AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23290165 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 20078462 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz frequency, 4.9 seconds per train, inter-train interval of 30 seconds, 20 trains per session, total 10 sessions)
Number of subjects: 45
Study 20078462 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 45
Study 17944760 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (n = 28)
Number of subjects: 62
Study 17944760 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy intervention (n = 34)
Number of subjects: 62
Study 15627538 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine 10 mg
Number of subjects: 43
Study 15627538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 10 mg + Phenylephrine 40 microg
Number of subjects: 43
Study 11877567 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan, 50 mg/d
Number of subjects: 16
Study 11877567 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 10200836 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural context
Number of subjects: 40
Study 10200836 — intervention group
Group type: COMPARATOR
Intervention: Simulated context
Number of subjects: 40
Study 7773815 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motion in combination with continuous passive motion (CPM)
Number of subjects: 34
Study 7773815 — intervention group
Group type: COMPARATOR
Intervention: Early active motion only (AM)
Number of subjects: 34
Study 1449275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 20 micrograms kg‐1
Number of subjects: 60
Study 1449275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 50 micrograms kg‐1
Number of subjects: 60
Study 1449275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 100 micrograms kg‐1
Number of subjects: 60
Study 1449275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micrograms kg‐1
Number of subjects: 60
Study 1449275 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with the same dose of ivermectin after six months
Number of subjects: 60
Study 1449275 — intervention group
Group type: COMPARATOR
Intervention: No retreatment at six months
Number of subjects: 60
Study 1449275 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects of ivermectin
Number of subjects: 60
Study 3904380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 30
Study 3904380 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 30
Study 3904380 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (Group II)
Number of subjects: 30
Study 3904380 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (after mexiletine)
Number of subjects: 30
Study 3904380 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality in Group II
Number of subjects: 30
Study 31760487 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (immediate motion exercises)
Number of subjects: 100
Study 31760487 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization (3 weeks)
Number of subjects: 100
Study 31760487 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization
Number of subjects: 100
Study 31760487 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization
Number of subjects: 100
Study 30193556 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% Concurrent and 100% Terminal (50% C & 100% T)
Number of subjects: 21
Study 30193556 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% Concurrent and 100% Terminal (0% C & 100% T)
Number of subjects: 21
Study 30193556 — intervention group
Group type: COMPARATOR
Intervention: 100% Concurrent and Terminal (100% C&T)
Number of subjects: 21
Study 27392045 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten (20 g/day)
Number of subjects: 18
Study 27392045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26234970 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive instruction during ten two‐hour sessions
Number of subjects: 40
Study 26234970 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching method
Number of subjects: 40
Study 24439191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftazidime treatment
Number of subjects: 70
Study 24439191 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis of antibiotics)
Number of subjects: 70
Study 18997159 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic medications
Number of subjects: 398
Study 18997159 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of elevated weight
Number of subjects: 398
Study 18997159 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatrists with more than 12 patients with schizophrenia in their caseload
Number of subjects: 398
Study 18620485 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro training model using chicken posterior trunks and porcine colons (Group A)
Number of subjects: 40
Study 18620485 — intervention group
Group type: COMPARATOR
Intervention: Chicken skin model (Group B)
Number of subjects: 40
Study 16364529 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslexic subjects
Number of subjects: 10
Study 16364529 — intervention group
Group type: COMPARATOR
Intervention: Attention shifting task
Number of subjects: 10
Study 12788251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder subjects
Number of subjects: 26
Study 12788251 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 26
Study 10979643 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + amino acid composition (glutaminic acid, glycine, cysteine)
Number of subjects: 60
Study 10979643 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + preductal
Number of subjects: 60
Study 10979643 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ST)
Number of subjects: 60
Study 7612386 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PP) therapy only
Number of subjects: 7
Study 7612386 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PP) + high dose intravenous methylprednisolone therapy (pulse therapy)
Number of subjects: 7
Study 7612386 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Plasmapheresis (PP) + pulse therapy
Number of subjects: 7
Study 2198157 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirazolac (300-600 mg b.i.d.)
Number of subjects: 119
Study 2198157 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (25-50 mg t.i.d.)
Number of subjects: 119
Study 490805 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation supplemented with partial venoarterial bypass (42 patients)
Number of subjects: 90
Study 490805 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (48 patients)
Number of subjects: 90
Study 490805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality in patients with pulmonary embolism and posttraumatic acute respiratory failure
Number of subjects: 90
Study 490805 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO support
Number of subjects: 90
Study 31537689 — intervention group
Group type: EXPERIMENTAL
Intervention: KMT2D mutations
Number of subjects: 0
Study 31537689 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 disruption
Number of subjects: 0
Study 31537689 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPI-genetic index
Number of subjects: 0
Study 31537689 — intervention group
Group type: COMPARATOR
Intervention: Conventional or intensified chemotherapy
Number of subjects: 0
Study 30444744 — intervention group
Group type: EXPERIMENTAL
Intervention: Methocarbamol
Number of subjects: 100
Study 30444744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28516519 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (ET) 3 times/week for 12 months
Number of subjects: 320
Study 28516519 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 320
Study 26395866 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (125 mg orally)
Number of subjects: 16
Study 23436087 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastrectomy for gastric cancer
Number of subjects: 164
Study 23436087 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass for morbid obesity
Number of subjects: 164
Study 21515839 — intervention group
Group type: EXPERIMENTAL
Intervention: First gluten exposure at age 12 months (late-exposure group)
Number of subjects: 150
Study 21515839 — intervention group
Group type: COMPARATOR
Intervention: First gluten exposure at age 6 months (control group)
Number of subjects: 150
Study 18380975 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct composite inlays
Number of subjects: 163
Study 18380975 — intervention group
Group type: COMPARATOR
Intervention: Traditional composite fillings
Number of subjects: 163
Study 16984550 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with propofol
Number of subjects: 121
Study 16984550 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with midazolam
Number of subjects: 121
Study 16984550 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 121
Study 12975594 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbiofan (50 mg BID)
Number of subjects: 0
Study 12975594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10947150 — intervention group
Group type: COMPARATOR
Intervention: SMART methodology
Number of subjects: 240
Study 10947150 — intervention group
Group type: COMPARATOR
Intervention: SMART models for renal and liver function indicators
Number of subjects: 240
Study 10947150 — intervention group
Group type: COMPARATOR
Intervention: SMART hematologic/coagulation models
Number of subjects: 240
Study 10947150 — intervention group
Group type: COMPARATOR
Intervention: SMART dichotomous models
Number of subjects: 240
Study 9172027 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of rocuronium 0.06 mg/kg followed two minutes later by an intubating dose of rocuronium 0.54 mg/kg
Number of subjects: 42
Study 9172027 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo injection followed two minutes later by rocuronium 0.6 mg/kg
Number of subjects: 42
Study 8115731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono-Pen XL
Number of subjects: 40
Study 8115731 — intervention group
Group type: COMPARATOR
Intervention: Manometer readings
Number of subjects: 40
Study 3549843 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin, 100 mg per day
Number of subjects: 6
Study 3549843 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo capsules
Number of subjects: 6
Study 3549843 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 6
Study 29734566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO₂)
Number of subjects: 71
Study 29734566 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 71
Study 26915984 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg bid
Number of subjects: 1231
Study 26915984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1231
Study 23685020 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index (CCI)
Number of subjects: 221
Study 23685020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (HTN)
Number of subjects: 221
Study 23685020 — intervention group
Group type: COMPARATOR
Intervention: CCI ≥ 7 vs CCI = 6
Number of subjects: 221
Study 23093731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm in Gothenburg
Number of subjects: 0
Study 23093731 — intervention group
Group type: COMPARATOR
Intervention: Control arm in Gothenburg
Number of subjects: 0
Study 23093731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm in Rotterdam
Number of subjects: 0
Study 23093731 — intervention group
Group type: COMPARATOR
Intervention: Control arm in Rotterdam
Number of subjects: 0
Study 20821816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 0
Study 20821816 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 18432483 — intervention group
Group type: EXPERIMENTAL
Intervention: Idea improvement during recall‐own plagiarism task
Number of subjects: 0
Study 18432483 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent ratings during generate‐new plagiarism task
Number of subjects: 0
Study 18432483 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on idea quality from independent judges
Number of subjects: 0
Study 15730413 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhGH (0.1 U/kg/day)
Number of subjects: 69
Study 15730413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhGH (0.2 U/kg/day)
Number of subjects: 69
Study 15730413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 12964121 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV(+)/HTLV-II(-)
Number of subjects: 385
Study 12964121 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV(-)/HTLV-II(+)
Number of subjects: 385
Study 12964121 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV(+)/HTLV-II(+)
Number of subjects: 385
Study 12964121 — intervention group
Group type: EXPERIMENTAL
Intervention: HTLV-II infection in white subjects
Number of subjects: 385
Study 12964121 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean HCV load
Number of subjects: 385
Study 12964121 — intervention group
Group type: EXPERIMENTAL
Intervention: Study site
Number of subjects: 385
Study 10546695 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple short‐bout exercise with home exercise equipment (SBEQ)
Number of subjects: 148
Study 10546695 — intervention group
Group type: COMPARATOR
Intervention: Multiple short‐bout exercise (SB)
Number of subjects: 148
Study 10546695 — intervention group
Group type: COMPARATOR
Intervention: Long‐bout exercise (LB)
Number of subjects: 148
Study 10546695 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise participation (more than 200 min/wk)
Number of subjects: 148
Study 10546695 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (LB, SB, SBEQ)
Number of subjects: 148
Study 8655980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraderal BCG
Number of subjects: 0
Study 8655980 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous BCG
Number of subjects: 0
Study 1675849 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (300 mg)
Number of subjects: 14
Study 1675849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6384844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 gel
Number of subjects: 45
Study 6384844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg PGE2 gel
Number of subjects: 45
Study 6384844 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 45
Study 30340932 — intervention group
Group type: EXPERIMENTAL
Intervention: Early routine treatment (ERT)
Number of subjects: 202
Study 30340932 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (CT)
Number of subjects: 202
Study 30297352 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) at 660 nm, power 100 mW, radiant exposure: 177 J/cm2, 0.5J per point, applied 2 times/week for 1 month.
Number of subjects: 44
Study 30297352 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate 0.05%, applied three times a day for 30 days.
Number of subjects: 44
Study 26258496 — intervention group
Group type: EXPERIMENTAL
Intervention: Daylight-mediated photodynamic therapy (DL-PDT)
Number of subjects: 70
Study 26258496 — intervention group
Group type: COMPARATOR
Intervention: Light-emitting diode photodynamic therapy (LED-PDT)
Number of subjects: 70
Study 25151042 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-exposed/MCV4 group
Number of subjects: 0
Study 25151042 — intervention group
Group type: EXPERIMENTAL
Intervention: MPSV4 in PSV-exposed/MPSV4 group
Number of subjects: 0
Study 25151042 — intervention group
Group type: EXPERIMENTAL
Intervention: MCV4 in PSV-naïve group
Number of subjects: 0
Study 25151042 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 0
Study 21481104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet radiation (UVR)
Number of subjects: 7
Study 21481104 — intervention group
Group type: COMPARATOR
Intervention: Sham UVR (filtered UVR)
Number of subjects: 7
Study 20027351 — intervention group
Group type: COMPARATOR
Intervention: Ultralow doses of antibodies to human IFN-gamma (anaferon pediatric formulation and anaferon)
Number of subjects: 0
Study 20027351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17363130 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ratio 30:2
Number of subjects: 130
Study 17363130 — intervention group
Group type: COMPARATOR
Intervention: Compression ratio 15:2
Number of subjects: 130
Study 15295747 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute cryotherapy treatment (1-kg ice bag application)
Number of subjects: 30
Study 15295747 — intervention group
Group type: COMPARATOR
Intervention: No ice treatment (control)
Number of subjects: 30
Study 11591611 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 281
Study 11591611 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 281
Study 11591611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 281
Study 9677555 — intervention group
Group type: EXPERIMENTAL
Intervention: Peribulbar injection (9 ml of anaesthetic from an inferotemporal site)
Number of subjects: 59
Study 9677555 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar injection (local anaesthetic through conjunctiva and facialis blockade)
Number of subjects: 59
Study 8303829 — intervention group
Group type: EXPERIMENTAL
Intervention: Kicking to move a block mobile displaying horizontal and vertical lines (textons) arranged as L, T, or +
Number of subjects: 0
Study 8303829 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed recognition tested at 0, 1, 3, 5, 7, or 9 days
Number of subjects: 0
Study 2467588 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 1.8 mg iv every 8 min as required
Number of subjects: 75
Study 2467588 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 18 mg iv every 8 min as required
Number of subjects: 75
Study 2467588 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymorphone 0.3 mg iv every 8 min as required
Number of subjects: 75
Study 29439526 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergy 1 (10 g/day)
Number of subjects: 34
Study 29439526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin; 7 g/day)
Number of subjects: 34
Study 28224442 — intervention group
Group type: COMPARATOR
Intervention: SAP (Strength, Agility, and Secondary Prevention treatment)
Number of subjects: 40
Study 28224442 — intervention group
Group type: COMPARATOR
Intervention: SAP+PERT (Strength, Agility, and Secondary Prevention treatment plus Perturbation Training)
Number of subjects: 40
Study 28224442 — intervention group
Group type: COMPARATOR
Intervention: SAP
Number of subjects: 40
Study 28224442 — intervention group
Group type: COMPARATOR
Intervention: SAP+PERT
Number of subjects: 40
Study 25670755 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-developed asthma decision support system integrated within MOXXI
Number of subjects: 4447
Study 25670755 — intervention group
Group type: COMPARATOR
Intervention: Control group using the Medical Office of the 21st century (MOXXI) system
Number of subjects: 4447
Study 22441680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal stent
Number of subjects: 20
Study 22441680 — intervention group
Group type: COMPARATOR
Intervention: No stenting
Number of subjects: 20
Study 21503122 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg one hour before anesthesia induction and 200 mg q12 h for five consecutive days after surgery
Number of subjects: 37
Study 21503122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study 19451500 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatologic consultation
Number of subjects: 631
Study 19451500 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 631
Study 16679325 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular electro-acupuncture (EA, n = 32)
Number of subjects: 94
Study 16679325 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (A, n = 32)
Number of subjects: 94
Study 16679325 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesia with remifentanil (CO, n = 30)
Number of subjects: 94
Study 15358701 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at 1,000 microg.day(‐1) followed by reductions to 500, 200, and 100 microg.day(‐1)
Number of subjects: 55
Study 15358701 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) at 1,000 and 500 microg.day(‐1)
Number of subjects: 55
Study 15358701 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) at 200 microg.day(‐1)
Number of subjects: 55
Study 11301674 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive palliative care
Number of subjects: 183
Study 11301674 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 183
Study 9280187 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 22
Study 9280187 — intervention group
Group type: COMPARATOR
Intervention: Egg white
Number of subjects: 22
Study 9280187 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha concentration
Number of subjects: 22
Study 9280187 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 concentration
Number of subjects: 22
Study 8100911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine given at induction of anaesthesia (iv pre)
Number of subjects: 60
Study 8100911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine given 1 hour before operation (im pre)
Number of subjects: 60